Beginning Feb. 3, you will have a chance to share your feedback on working at UAB via our biennial campus engagement survey, ...

To help track where we are on this journey, and to amplify success stories, in this Collection we present studies that assess progress or that showcase interventions that have made a difference.

AIM ImmunoTech Inc. announced progress in its clinical development of Ampligen® (rintatolimod), particularly in addressing critical unmet medical needs in areas like pancreatic cancer and Long-COVID.

Creating two distinct classifications of “clinical obesity” and “pre-clinical obesity” would provide more accurate diagnosis and more personalised treatment, it argued.

The company's clinical progress has been marked by several key ... However, investors should note the stock's significant volatility, with a beta of 2.02 and a 71.65% decline over the past year.

Program Advancing to Next Phase of Clinical Development in Multiple Myeloma and Non-Hodgkin’s Lymphoma CFT1946 Phase 1 Trial Continues to Progress in BRAF V600X Solid Tumors With Monotherapy ...

14, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, “Instil”), today announced clinical progress of IMM2510/SYN-2510 in China by its collaborator, ImmuneOnco ...

14, 2025 (GLOBE NEWSWIRE) -- Instil Bio, Inc. (Nasdaq: TIL, “Instil”), today announced clinical progress of IMM2510/SYN-2510 in China by its collaborator, ImmuneOnco Biopharmaceuticals ...

Instil Bio (TIL)y announced clinical progress of IMM2510/SYN-2510 in China by its collaborator, ImmuneOnco Biopharmaceuticals. ImmuneOnco announced that the first patient has been dosed in its ...